[Soft tissue sarcoma in children and adolescents: experiences of the cooperative Soft Tissue Sarcoma Group Studies (CWS-81 - 96)].
The very heterogeneous group of paediatric soft tissue sarcomas account for approximately 7 % of all malignant childhood tumours. More than one half of all cases are rhabdomyosarcomas, some of the over 20 entities are very rare. The prognosis and biology of soft tissue sarcomas in children and adolescents vary greatly depending on histological subtype, the age of the patient, the primary site, the tumour size, tumour invasiveness and the extent of disease at diagnosis. Since 1981, 2918 children and adolescents with soft tissue sarcomas were treated prospectively according to the common treatment protocols of the Cooperative Soft Tissue Sarcoma Study Group (CWS-81 - 96). The known prognostic factors were used to develop a more and more detailed risk stratification. The multimodal treatment includes the use of surgery, chemotherapy and radiotherapy and should be planned by a multidisciplinary team. That way, an overall survival of nearly 70 % over all risk groups could be achieved.
Brecht
I B
IB
Abteilung für Pädiatrische Onkologie und Hämatologie, Olgahospital Stuttgart.
Treuner
J
J
D000293:Adolescent; D024221:Antineoplastic Protocols; D002648:Child; D002675:Child, Preschool; D003131:Combined Modality Therapy; D003238:Connective Tissue / Q000473:pathology; D005260:Female; D005858:Germany; D006801:Humans; D007223:Infant; D033183:Interdisciplinary Communication; D008297:Male; D018482:Muscle, Skeletal / Q000473:pathology; D009361:Neoplasm Invasiveness / Q000473:pathology; D009367:Neoplasm Staging; D010348:Patient Care Team; D011379:Prognosis; D011446:Prospective Studies; D012509:Sarcoma / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D015996:Survival Rate